| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02904850 | Lung Cancer | Biological: group of patients | University Hospital, Strasbourg, France | | 2014-06-01 | 2016-09-13 |
| NCT00482625 | Intraductal Papillary Mucinous Neoplasm of the Pancreas|Recurrent Pancreatic Cancer|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer | Drug: erlotinib hydrochloride|Procedure: conventional surgery|Other: immunohistochemistry staining method|Genetic: protein expression analysis|Procedure: biopsy|Other: pharmacological study|Other: laboratory biomarker analysis | National Cancer Institute (NCI) | Phase 2 | 2007-06-01 | 2014-10-07 |
| NCT00925769 | Pancreatic Cancer | Drug: bevacizumab [Avastin]|Drug: capecitabine [Xeloda]|Drug: erlotinib [Tarceva] | Hoffmann-La Roche | Phase 1 | 2009-01-01 | 2015-07-13 |
| NCT00124657 | Brain and Central Nervous System Tumors | Drug: Erlotinib hydrochloride | St. Jude Children's Research Hospital|Rady Children's Hospital, San Diego|Duke University | Phase 1|Phase 2 | 2005-03-01 | 2015-10-29 |
| NCT00754494 | Adenomatous Polyp|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage I Colon Cancer|Stage I Rectal Cancer|Stage IIA Colon Cancer|Stage IIA Rectal Cancer|Stage IIB Colon Cancer|Stage IIB Rectal Cancer|Stage IIC Colon Cancer|Stage IIC Rectal Cancer|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer | Drug: erlotinib hydrochloride|Other: placebo|Other: laboratory biomarker analysis | National Cancer Institute (NCI) | Phase 2 | 2008-07-01 | 2014-12-22 |
